Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Study ID
NCT04803318
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Key Dates

Start date
Jan 1, 2021
Status verified
Jun 2024
Primary completion
Jan 1, 2029
Completion
Jan 1, 2037

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination treatment of 3 inhibitors
    Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.

Primary Outcome Measure

Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment. [ Time Frame: up to 36 months ]

Central Contacts

Related Studies